Vanguard Group Inc. boosted its stake in shares of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) by 6.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 681,712 shares of the biotechnology company’s stock after buying an additional 38,892 shares during the period. Vanguard Group Inc. owned about 3.02% of Concert Pharmaceuticals worth $11,630,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the stock. Quantbot Technologies LP purchased a new position in shares of Concert Pharmaceuticals during the first quarter valued at about $138,000. Hillsdale Investment Management Inc. purchased a new position in shares of Concert Pharmaceuticals during the first quarter valued at about $143,000. American International Group Inc. raised its position in shares of Concert Pharmaceuticals by 7.1% in the first quarter. American International Group Inc. now owns 10,156 shares of the biotechnology company’s stock valued at $173,000 after buying an additional 677 shares during the period. Rockefeller Financial Services Inc. raised its position in shares of Concert Pharmaceuticals by 19.6% in the first quarter. Rockefeller Financial Services Inc. now owns 10,289 shares of the biotechnology company’s stock valued at $176,000 after buying an additional 1,689 shares during the period. Finally, Oxford Asset Management bought a new position in shares of Concert Pharmaceuticals during the first quarter worth $237,000. 62.37% of the stock is owned by institutional investors.

Shares of Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) traded up 0.93% during trading on Thursday, reaching $15.13. 34,416 shares of the company were exchanged. Concert Pharmaceuticals, Inc. has a 52-week low of $7.11 and a 52-week high of $19.11. The firm’s market cap is $343.25 million. The stock’s 50-day moving average is $14.34 and its 200-day moving average is $14.27.

Concert Pharmaceuticals (NASDAQ:CNCE) last released its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.58) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.62) by $0.04. The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.20 million. Concert Pharmaceuticals had a negative net margin of 60,681.70% and a negative return on equity of 61.98%. Equities research analysts predict that Concert Pharmaceuticals, Inc. will post ($2.18) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Concert Pharmaceuticals, Inc. (CNCE) Shares Bought by Vanguard Group Inc.” was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another site, it was illegally copied and republished in violation of international copyright law. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/08/31/concert-pharmaceuticals-inc-cnce-shares-bought-by-vanguard-group-inc.html.

A number of equities analysts recently weighed in on CNCE shares. HC Wainwright started coverage on shares of Concert Pharmaceuticals in a research note on Monday, July 24th. They issued a “buy” rating and a $20.00 target price for the company. Zacks Investment Research lowered shares of Concert Pharmaceuticals from a “buy” rating to a “sell” rating in a research note on Monday, May 8th. Stifel Nicolaus reaffirmed a “buy” rating and issued a $30.00 target price (down from $31.00) on shares of Concert Pharmaceuticals in a research note on Monday, July 10th. Aegis reaffirmed a “buy” rating and issued a $25.00 target price on shares of Concert Pharmaceuticals in a research note on Monday, June 12th. Finally, BidaskClub lowered shares of Concert Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. One analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company’s stock. Concert Pharmaceuticals has an average rating of “Buy” and an average price target of $24.83.

Concert Pharmaceuticals Company Profile

Concert Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drugs. The Company operates through the development of pharmaceutical products on its own behalf or in collaboration with others. The Company’s deuterated chemical entity platform (DCE Platform), has potential across various therapeutic areas.

Institutional Ownership by Quarter for Concert Pharmaceuticals (NASDAQ:CNCE)

Receive News & Stock Ratings for Concert Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Concert Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.